GPCR Autoantibody Diagnostics (various targets)
Post-COVID Conditions (Long COVID), POTS, ME/CFS, Sjögren's Syndrome
Research/DevelopmentActive
Key Facts
Indication
Post-COVID Conditions (Long COVID), POTS, ME/CFS, Sjögren's Syndrome
Phase
Research/Development
Status
Active
Company
About CellTrend
CellTrend is a niche biotechnology firm with a dual business model combining contract research services and proprietary diagnostic development. Its core expertise lies in cell-based bioassays and ELISA-based detection of autoantibodies, particularly against G-protein coupled receptors (GPCRs), with a flagship patented test for Angiotensin-II-Receptor-1 antibodies. The company is strategically positioned in the growing field of post-infectious and autoimmune disease diagnostics, especially for conditions like Long COVID, POTS, and ME/CFS, while serving pharmaceutical clients through its CRO services.
View full company profile